|Videos|March 15, 2017
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
Author(s)Kathleen N. Moore M.D.
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Exousia Pro Orphan Drug Designation in Glioma
2
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
3
What to Know About the FDA Approval of Blenrep for Multiple Myeloma
4
Advancing Research Offers Hope for Patients With Liver Cancer
5
